Europe Erectile Dysfunction Drugs Market Size & Outlook
The erectile dysfunction drugs market in Europe is expected to reach a projected revenue of US$ 1,470.2 million by 2033. A compound annual growth rate of 10.2% is expected of Europe erectile dysfunction drugs market from 2026 to 2033.
Revenue, 2025 (US$M)
$685.7
Estimate, 2026 (US$M)
$746.6
Forecast, 2033 (US$M)
$1,470.2
CAGR, 2026 - 2033
10.2%
Global Market
Related Markets
Europe erectile dysfunction drugs market highlights
- The Europe erectile dysfunction drugs market generated a revenue of USD 685.7 million in 2025.
- The market is expected to grow at a CAGR of 10.2% from 2026 to 2033.
- In terms of segment, viagra (sildenafil citrate) was the largest revenue generating product in 2025.
- Other Drugs is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 685.7 million |
| Market revenue in 2033 | USD 1,470.2 million |
| Growth rate | 10.2% (CAGR from 2026 to 2033) |
| Largest segment | Viagra (sildenafil citrate) |
| Fastest growing segment | Other Drugs |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cialis (Tadalafil), Stendra/Spedra (avanafil), Viagra (sildenafil citrate), Levitra/Staxyn (vardenafil), Other Drugs |
| Key market players worldwide | Pfizer Inc, Eli Lilly and Co, Teva Pharmaceutical Industries Ltd, Sanofi SA, Sun Pharmaceutical Industries, Bayer AG, Petros Pharmaceuticals Inc Ordinary Shares, Cipla Ltd DR, Icahn Enterprises LP Depositary Units Repr Units of LP Interests, Auxilium Pharmaceuticals |
Other key industry trends
- In terms of revenue, Europe region accounted for 21.7% of the global erectile dysfunction drugs market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,443.1 million by 2033.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Erectile Dysfunction Drugs Market
Erectile dysfunction drugs market segmentation & scope
Erectile Dysfunction Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Cipla Ltd DR | View profile | 38,955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | www.cipla.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | www.sunpharma.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Petros Pharmaceuticals Inc Ordinary Shares | View profile | 21 | 1185 Avenue of the Americas, 3rd Floor, New York, NY, United States, 10036 | www.petrospharma.com |
| Icahn Enterprises LP Depositary Units Repr Units of LP Interests | View profile | 15,038 | 16690 Collins Avenue, PH-1, Penthouse Suite, Sunny Isles Beach, FL, United States, 33160 | www.ielp.com |
| Auxilium Pharmaceuticals | View profile | 501-1000 | Centerbrook, Connecticut, United States, North America | auxilium.com |
Europe erectile dysfunction drugs market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Erectile Dysfunction Drugs Market Outlook will help companies and investors design strategic landscapes.
Viagra (Sildenafil Citrate) was the largest segment with a revenue share of 62.1% in 2025.
Horizon Databook has segmented the Europe erectile dysfunction drugs market based on cialis (tadalafil), stendra/spedra (avanafil), viagra (sildenafil citrate), levitra/staxyn (vardenafil), other drugs covering the revenue growth of each sub-segment from 2021 to 2033.
- Europe Erectile Dysfunction Drugs Market Product Outlook (Revenue, USD Million , 2021-2033)
- Viagra (sildenafil citrate)
- Cialis (Tadalafil)
- Levitra/Staxyn (vardenafil)
- Stendra/Spedra (avanafil)
- Zydena (udenafil)
- Other Drugs
- Europe Erectile Dysfunction Drugs Market Mode of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral Mode of Administration
- Injectable Mode of Administration
- Other Modes of Administration
Reasons to subscribe to erectile dysfunction drugs market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of erectile dysfunction drugs market databook
- Our clientele includes a mix of erectile dysfunction drugs market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe erectile dysfunction drugs market, including forecasts for subscribers. This continent databook contains high-level insights into Europe erectile dysfunction drugs market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Erectile Dysfunction Drugs Market, 2021-2033 (US$M)
Europe erectile dysfunction drugs market statistics, by product, 2021-2033 (US$M)
